AbbVie Income After Taxes 2010-2024 | ABBV

AbbVie annual/quarterly income after taxes history and growth rate from 2010 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
  • AbbVie income after taxes for the quarter ending September 30, 2024 was $1.564B, a 12.18% decline year-over-year.
  • AbbVie income after taxes for the twelve months ending September 30, 2024 was $5.133B, a 21.29% decline year-over-year.
  • AbbVie annual income after taxes for 2023 was $4.873B, a 58.86% decline from 2022.
  • AbbVie annual income after taxes for 2022 was $11.845B, a 2.56% increase from 2021.
  • AbbVie annual income after taxes for 2021 was $11.549B, a 149.87% increase from 2020.
AbbVie Annual Income After Taxes
(Millions of US $)
2023 $4,873
2022 $11,845
2021 $11,549
2020 $4,622
2019 $7,882
2018 $5,687
2017 $5,309
2016 $5,953
2015 $5,144
2014 $1,774
2013 $4,128
2012 $5,275
2011 $3,433
2010 $4,178
2009 $4,637
AbbVie Quarterly Income After Taxes
(Millions of US $)
2024-09-30 $1,564
2024-06-30 $1,373
2024-03-31 $1,372
2023-12-31 $824
2023-09-30 $1,781
2023-06-30 $2,027
2023-03-31 $241
2022-12-31 $2,472
2022-09-30 $3,952
2022-06-30 $928
2022-03-31 $4,493
2021-12-31 $4,045
2021-09-30 $3,180
2021-06-30 $769
2021-03-31 $3,555
2020-12-31 $38
2020-09-30 $2,313
2020-06-30 $-739
2020-03-31 $3,010
2019-12-31 $2,801
2019-09-30 $1,884
2019-06-30 $741
2019-03-31 $2,456
2018-12-31 $-1,826
2018-09-30 $2,747
2018-06-30 $1,983
2018-03-31 $2,783
2017-12-31 $52
2017-09-30 $1,631
2017-06-30 $1,915
2017-03-31 $1,711
2016-12-31 $1,391
2016-09-30 $1,598
2016-06-30 $1,610
2016-03-31 $1,354
2015-12-31 $1,517
2015-09-30 $1,239
2015-06-30 $1,366
2015-03-31 $1,022
2014-12-31 $-810
2014-09-30 $506
2014-06-30 $1,098
2014-03-31 $980
2013-12-31 $1,128
2013-09-30 $964
2013-06-30 $1,068
2013-03-31 $968
2012-12-31 $1,540
2012-09-30 $1,585
2012-06-30 $1,267
2012-03-31 $883
2011-12-31 $2,710
2011-09-30 $4,409
2011-06-30 $4,274
2011-03-31 $723
2010-12-31
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $352.544B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51